Simultaneous infection with hepatitis delta virus (HDV) and hepatitis B virus (HBV) in humans is often associated with severe viral liver disease including fulminant hepatitis. Since HBV is thought to be noncytopathic to the hepatocyte, the enhanced disease severity observed during dual infection has been attributed to either simultaneous immune responses against the two viruses or direct cytotoxic effects of HDV products on the hepatocyte or both. To examine these alternate possibilities, we produced transgenic mice that express the small and large delta antigens (HDAg) in hepatocyte nuclei at levels equal to those observed during natural HDV infection. No biological or histopathological evidence of liver disease was detectable during 18 months of observation, suggesting that neither the large nor small form of HDAg is directly cytopathic to the hepatocyte in vivo.
Simultaneous infection with hepatitis delta virus (HDV) and hepatitis B virus (HBV) in humans is often associated with severe viral liver disease including fulminant hepatitis. Since HBV is thought to be noncytopathic to the hepatocyte, the enhanced disease severity observed during dual infection has been attributed to either simultaneous immune responses against the two viruses or direct cytotoxic effects of HDV products on the hepatocyte or both. To examine these alternate possibilities, we produced transgenic mice that express the small and large delta antigens (HDAg) in hepatocyte nuclei at levels equal to those observed during natural HDV infection. No biological or histopathological evidence of liver disease was detectable during 18 months of observation, suggesting that neither the large nor small form of HDAg is directly cytopathic to the hepatocyte in vivo.
Hepatitis delta virus (HDV) is a small single-stranded, circular RNA virus whose genome structure resembles that of plant viroids (43) . This virus codes for only one protein product, the delta antigen (HDAg), which serves as its nucleocapsid, and is highly pathogenic, frequently causing fulminant hepatitis. HDAg is encoded on antigenomic RNA and is expressed in the cell via a cytoplasmic polyadenylated RNA of about 0.8 kb in size (7, 18) . HDAg consists of two protein species of 214 and 195 amino acids, termed large and small HDAg, respectively. During HDV replication, a specific transition occurs at the second position of the amber termination codon (UAG to UGG) of the small HDAg open reading frame (ORF), thereby increasing the length of the ORF and allowing synthesis of the large HDAg containing a 19-amino-acid C-terminal extension (4, 23, 45) .
Despite their extensive primary structure similarity, the small and large HDAg play very different functional roles in the life cycle of the virus. The small HDAg is required for genome replication, while the large HDAg is required for genome packaging (7, 22, 34) . In addition, the large HDAg inhibits HDV genome replication (6) . Virus particle formation requires not only HDV RNA and HDAg, which together form the nucleocapsid, but also the surface antigen of HBV (HBsAg), which provides the viral envelope which is necessary for viral infectivity (39) .
Because of this obligatory association with HBV, characterization of the nature and extent of the disease attributable to HDV alone has been difficult to assess. Experimental HDV infection of animals that support hepadnavirus replication has been successful (29, 32) , and considerable information concerning the natural history of HDV infection has been gathered from these animal models. However, it remains unclear whether HDV causes liver disease by a direct cytotoxic effect t Manuscript 8077-MEM of The Scripps Research Institute.
or by indirect, immune system-mediated destruction of the infected hepatocytes.
To evaluate the potential hepatocytotoxic properties of HDAg in vivo, we have developed transgenic mice that express the small and large forms of HDAg in the liver, separately and in combination with the small and large envelope polypeptides of HBV.
MATERLILS AND METHODS
Plasmid construction. To ensure high-level expression in the liver, we placed the HDAg ORF under the transcriptional control of the mouse albumin promoter. We used the 2333-Al expression vector generously provided by Richard Palmiter (University of Washington). The 2335-Al vector is similar to pUC18-Alb(e/p) described previously (15) , except that the albumin enhancer/promoter NheI-KpnI DNA fragment was inserted into pBluescript SK+ (Stratagene, La Jolla, Calif.) instead of pUC18. Briefly, in the 2335-Al vector, the albumin promoter is linked to the 2-kbp NheI-BamHI enhancer fragment located 8 kbp upstream of the albumin promoter in the mouse genome that is known to confer high-level expression of the human growth hormone in the mouse liver (28) . The large HDAg ORF was generated from plasmid pECE-HDV-L (5) by BamHI-and-BglII double digestion. The small HDAg construct was generated by inserting at the 2335-Al BamHI site a PCR-generated fragment containing nucleotides 1663 to 944 (in antigenomic orientation) of the HDV sequence (25 (16) .
Identification of HDAg DNA-positive transgenic mice expressing. Genomic DNA and total cellular RNA was prepared from tissues by standard techniques as previously described (11) Western immunoblot analysis. Purified nuclei in storage buffer were pelleted by centrifugation at 5,000 x g for 2 min, resuspended in 200 p.l of loading buffer, and boiled for 5 min.
Genomic DNA was sheared by forcing the sample through a 28.5-gauge needle before loading. Proteins were separated by sodium dodecyl sulfate-12% polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes as described previously (13) . Rabbit antidelta antibody (44) was used at a 1/500 dilution, and then a biotinylated anti-rabbit whole antibody and streptavidin-alkaline phosphatase conjugate (Amersham, Arlington Heights, Ill.) were used. The color reaction was developed with nitroblue tetrazolium and 5-bromo-4-chloro-3-indolylphosphate in diethanolamine buffer. To compare HDAg levels expressed in transgenic mouse livers and in HDV-infected chimpanzee and woodchuck livers, proteins from transgenic mouse livers were extracted by the guanidine-HCI procedure described previously (1). Guanidine-HCl-extracted liver samples from HDV-infected chimpanzee and woodchuck livers obtained at the peak of HDV infection were kindly provided by Katherine Bergmann and John Gerin (Georgetown University).
Immunostaining. Frozen liver sections (5 pLm thick) were fixed in ice-cold acetone (5 min). Human polyclonal antidelta antibody (AMAC, Westbrook, Maine) was applied at a 1/10 dilution in phosphate-buffered saline (PBS) overnight at 40C, and then biotinylated goat F(ab')2 affinity-isolated anti-human immunoglobulin G antibody (gamma chain specific) (Sigma Chemical Co., St. Louis, Mo.) at a 1/100 dilution at 4°C for 6 to 12 h and Extravidin-peroxidase were applied. The color reaction was developed with aminoethylcarbazole, and the slides were counterstained with Meyer's hematoxylin as previously described (8) .
Immunoelectron microscopy. Indirect immunostaining for nuclear localization of HDAg was performed with protein A-colloidal gold (8-nm particle size) as the electron-dense label. Preparation of the protein A-colloidal gold conjugate was performed as previously described (37, 38) .
Isolated nuclei were incubated with rabbit antidelta antibody at a 1/100 dilution in storage buffer overnight at 40C and washed four times with PBS. The nuclei were incubated with protein A-colloidal gold at a 1/100 dilution in PBS containing 0.02% polyethylene glycol (molecular weight, 20000) for 2 h at 4°C and then washed in PBS four times. Nuclei were fixed for 1 h at 4°C in PBS containing 1% glutaraldehyde and 4%o paraformaldehyde. After osmification in 1% aqueous solution of osmium tetroxide for 1 h at 40C, the nuclei were processed for Epon embedding. The ultrathin sections were examined with a Zeiss 109 electron microscope.
RESULTS
Description of the transgenic mouse lineages. (i) DNA analysis. Three transgenic mouse lineages containing the small HDAg construct (DS-186, DS-188, and DS-190) and one transgenic mouse lineage containing the large HDAg construct (DL-11) were derived. Southern blot analysis of SacI-digested genomic DNA revealed a distinct integration pattern for each lineage (Fig. IA) . For each lineage, the observed pattern is compatible with the presence of at least one full-length integrated fragment.
(ii) RNA analysis. Total RNA derived from the liver, kidney, spleen, stomach, small intestine, large intestine, testis, heart, lung, thymus, salivary glands, and brain from an adult DL-1 1 Northern blot analysis of total RNA (10 pLg) extracted from tissues of an DL-1 1 adult animal and hybridized with HDV and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) sequences. Lanes: 1, liver; 2, kidney; 3, spleen; 4, stomach; 5, small intestine; 6, large intestine; 7, testis; 8, heart; 9, lung; 10, thymus; 11, salivary glands; 12, brain.
genase (GAPDH) (10) sequences (Fig. IB) . HDV-specific RNA was detected only in the liver.
(iii) Protein analysis. HDAg was detected in the livers of all four lineages as illustrated in Fig. 2 27 and 24 kDa compatible with the sizes of the large and small HDAg, respectively (Fig. 3A) .
To estimate the level of HDAg expression in the transgenic mice relative to HDV-infected livers, we performed Western blotting with liver protein extracts from transgenic mice and from HDV-infected chimpanzee and woodchuck livers obtained at the peak of infection. Chimpanzee and woodchuck protein extracts were kindly provided by Katherine Bergmann Immunoelectron microscopy was performed with isolated DL-11 liver nuclei (Fig. 4) . Positive immunolabeling was observed in about 25% of the transgenic mouse liver nuclei, while no labeling was noted in any of the nontransgenic littermate control liver nuclei. As shown in Fig. 4A , the labeling is more intense around the nucleolus, presumably associated with the perinucleolar chromatin, and to a lesser extent among the chromatin fibrils in the nucleoplasm. The observed intranuclear localization of HDAg in the transgenic mice is similar to the HDAg localization reported in HDVinfected livers (20) .
(iv) Disease parameters. To determine whether HDAg expression was cytopathic to the hepatocyte, all four mouse lineages were examined for histological evidence of liver disease at monthly or bimonthly intervals for up to 18 months 5 . Serum ALT levels in HDAg transgenic mouse lineages. Mice were bled by retro-orbital phlebotomy with heparinized capillary tubes, and serum ALT activity was determined with a Paramax autoanalyzer as previously described (7) . Values are grouped for the three small HDAg transgenic lineages. The number of animals (n) in each category is shown. Results represent the mean ± standard error of the mean.
and for ultrastructural evidence of liver disease in lineage DL-11 at 2 months of age. No histopathological or ultrastructural (not shown) changes were associated with HDAg expression in any of the transgenic lineages. Serum alanine aminotransferase (ALT) activity as a biochemical parameter of liver disease was also monitored in the four transgenic mouse lineages. As shown in Fig. 5 , serum ALT levels remained within the normal range (less than 100 U/liter) over an 18-month observation period for DL-11 lineage and a 10-month observation period for the three DS lineages.
While expression of HDAg is not directly cytotoxic to the transgenic mouse hepatocyte in vivo, we tested the possibility that the expression of this antigen could sensitize the hepatocyte to the hepatocytotoxic effects of LPS, as we have reported for the large envelope polypeptide of HBV in lineage 107-5 (12) . None of the HDAg lineages displayed serum ALT elevation in response to 100 ,ug of LPS (1.6 x 106 endotoxin units) (serum ALT levels of 16 ± 11 U/liter for two transgenic mice expressing large HDAg and 44 ± 17 U/liter for three transgenic mice expressing small HDAg).
Because HDV infection occurs only in the context of a coexisting HBV infection, it is possible that simultaneous expression of HBV-and HDV-encoded antigens could be directly cytopathic to the hepatocyte. To evaluate this possibility, DL-11 transgenic mice were crossbred with HBsAgpositive transgenic lineage 107-5 that does not develop evidence of liver disease (12) . Effective HDAg and HBsAg coexpression was achieved in the hybrids, since HBsAg is expressed in virtually 100% of the hepatocytes in transgenic lineage 107-5. In no instance did we observe histopathological or biochemical evidence of liver cell injury in groups of three to seven single and double transgenic mice from all possible combinations monitored for up to 6 months of age (Table 1) .
Effect of HDAg on HBV expression. It has been shown that HDV superinfection leads to decreased hepadnavirus replication both in animal models (chimpanzees and woodchucks) and in humans (14, 21, 26, 27, 29, 32, 41) . This effect was not observed in the HDAg x HBsAg transgenic hybrids. Serum HBsAg levels were identical in the presence or absence of the large HDAg in groups of six single and seven double transgenic HDAg x HBsAg transgenic mice examined at 2 months of age (Table 1) . DISCUSSION In an attempt to elucidate the mechanisms of HDV pathogenesis, we developed a transgenic mouse model that reproduces the liver-specific expression of the small and large HDAgs. Western blot analysis demonstrated hepatic expression of both forms of HDAg. The expression of HDAg-specific RNA was restricted to the liver. In the hepatocyte, HDAg expression was limited to the nucleus, similar to that reported for HDV infection of humans and animal models (29, 31, 32) . The distribution of HDAg in transgenic mice was mainly nucleolar, with an additional prominent nucleoplasmic component in many cells. The same nuclear distribution observed in all four HDAg transgenic lineages suggests that the nuclear localization signal and conformation of the HDAg in transgenic mice faithfully reproduce the native structures of the large and small forms of HDAg. The intranuclear distribution of HDAg and its association with perinucleolar structures were further confirmed by immunoelectron microscopic observation. Thus, it appears that the expression of the two isoforms of HDAg in these transgenic mice reflects the characteristics of the HDAg found in infected livers. Therefore, any potential direct cytotoxic property associated with HDAg expression should be revealed in this model.
Because of the severity of the hepatic disease often associated with HDV infection and its temporal association with virus replication and expression (3, 17 and references therein), it has been postulated that HDV products may be directly cytotoxic to the hepatocyte, although evidence for immune system-mediated liver disease has also been reported (30) . Previous attempts to demonstrate the direct cytotoxicity of HDV or its products by using in vitro expression systems have led to contradictory results. For example, although most studies suggested that HDV or HDAg alone is not directly cytopathic (7, 19, 22, 40, 42) , one study based on inducible expression of small HDAg in clones derived from transfected cell lines suggested that small HDAg is cytopathic in vitro (9, 24) . Whether these contradictory results reflect qualitative variations in HDV genomes or quantitative effects of the level of expression or peculiarity of the studied clones remains to be elucidated. The results of the current study, however, suggest that the small and large HDAg are not directly cytopathic to the hepatocyte in vivo.
To further explore the potential cytopathic effect of HDAg expression in the hepatocyte, we considered that in natural infection, the expression of HDAg occurs in a cell that is also perturbed by the presence of HBV gene products and inflammatory mediators released in the liver in response to HBV infection.
To determine whether coexpression of HDAg and HBV gene products is directly cytopathic, we produced hybrid HDAg x HBsAg transgenic mice that express the gene products of both viruses. Colocalization of HBsAg with HDAg in the hepatocyte was not cytopathic in these animals.
We have previously demonstrated that noncytopathic concentrations of the HBV large envelope protein in the hepatocyte can sensitize the hepatocyte to the cytopathic effect of LPS (12) . In contrast, HDAg expression does not sensitize the hepatocyte to the cytotoxic effects of LPS.
Thus, it would appear that expression of HDAg, even in the presence of HBsAg, is not directly cytotoxic to the hepatocyte nor does it potentiate the hepatocyte to injury by LPS. This model obviously does not address the potential cytotoxicity of other aspects of the HDV infection cycle, such as HDV genome replication and interactions with the cellular transcription machinery.
HDV superinfection of patients with chronic HBV infection is often associated with a transient but marked reduction of HBV DNA and HBV core antigen within the liver and a decrease in circulating HBV DNA and HBV e antigen (14, 21) . The same is true for HDV superinfection of woodchuck hepatitis virus-infected woodchucks or HBV-infected chimpanzees (26, 27, 29, 32, 41) . We did not observe any apparent down-regulation in the secreted HBsAg in our hybrid HDAgHBsAg transgenic mice. These results suggest that downregulation of HBV replication by HDV is not due to a direct interaction between HDAg and HBsAg. Since this transgenic mouse model does not include all the steps of complete HDV or HBV replication cycles, it is likely that other aspects of the HDV life cycle are responsible for this effect. Alternatively, the repression of HBV replication during HDV infection could be generated indirectly by the host response against HDV, by inducing the release of inflammatory cytokines such as tumor necrosis factor alpha and gamma interferon which we have shown inhibit HBV gene expression in vivo (11, 12) .
